Stock Analysis on Net
Stock Analysis on Net

Bristol-Myers Squibb Co. (NYSE:BMY)

Statement of Comprehensive Income 

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Bristol-Myers Squibb Co., consolidated statement of comprehensive income

US$ in millions

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings (loss) (8,933) 8,040 6,345 7,014 (8,995)
Derivatives qualifying as cash flow hedges 374 (230) 54 415 (256)
Pension and postretirement benefits 90 (115) 145 206 (75)
Marketable debt securities — 2 (2) (9) 5
Foreign currency translation (156) 78 (210) (41) 7
Other comprehensive income/(loss), net of taxes and reclassifications to earnings 308 (265) (13) 571 (319)
Comprehensive income (loss) (8,625) 7,775 6,332 7,585 (9,314)
Comprehensive income attributable to noncontrolling interest (15) (15) (18) (20) (20)
Comprehensive income (loss) attributable to BMS (8,640) 7,760 6,314 7,565 (9,334)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Comprehensive income item Description The company
Net earnings (loss) attributable to BMS The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Bristol-Myers Squibb Co. net earnings (loss) attributable to BMS increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Comprehensive income (loss) attributable to BMS Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners. Bristol-Myers Squibb Co. comprehensive income (loss) attributable to BMS increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.